As of 2025-07-14, the EV/EBITDA ratio of Vyne Therapeutics Inc (VYNE) is 0.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VYNE's latest enterprise value is -4.55 mil USD. VYNE's TTM EBITDA according to its financial statements is -42.15 mil USD. Dividing these 2 quantities gives us the above VYNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 10.4x | 8.2x |
| Forward P/E multiples | 11.4x - 17.6x | 15.0x |
| Fair Price | (27.05) - (24.57) | (27.72) |
| Upside | -2004.8% - -1830.2% | -2052.0% |
| Date | EV/EBITDA |
| 2025-05-16 | 0.19 |
| 2025-05-15 | 0.18 |
| 2025-05-14 | 0.17 |
| 2025-05-13 | 0.15 |
| 2025-05-12 | 0.18 |
| 2025-05-09 | 0.16 |
| 2025-05-08 | 0.16 |
| 2025-05-07 | 0.13 |
| 2025-05-06 | 0.14 |
| 2025-05-05 | 0.10 |
| 2025-05-02 | 0.13 |
| 2025-05-01 | 0.14 |
| 2025-04-30 | 0.14 |
| 2025-04-29 | 0.11 |
| 2025-04-28 | 0.10 |
| 2025-04-25 | 0.10 |
| 2025-04-24 | -0.07 |
| 2025-04-23 | -0.06 |
| 2025-04-22 | -0.07 |
| 2025-04-21 | -0.04 |
| 2025-04-17 | -0.06 |
| 2025-04-16 | -0.04 |
| 2025-04-15 | -0.05 |
| 2025-04-14 | -0.02 |
| 2025-04-11 | 0.05 |
| 2025-04-10 | 0.08 |
| 2025-04-09 | 0.03 |
| 2025-04-08 | 0.07 |
| 2025-04-07 | 0.06 |
| 2025-04-04 | 0.05 |
| 2025-04-03 | 0.01 |
| 2025-04-02 | 0.02 |
| 2025-04-01 | 0.06 |
| 2025-03-31 | 0.04 |
| 2025-03-28 | -0.00 |
| 2025-03-27 | -0.03 |
| 2025-03-26 | -0.01 |
| 2025-03-25 | -0.02 |
| 2025-03-24 | -0.02 |
| 2025-03-21 | -0.01 |
| 2025-03-20 | 0.01 |
| 2025-03-19 | -0.03 |
| 2025-03-18 | -0.03 |
| 2025-03-17 | -0.07 |
| 2025-03-14 | -0.06 |
| 2025-03-13 | -0.08 |
| 2025-03-12 | -0.06 |
| 2025-03-11 | -0.07 |
| 2025-03-10 | -0.11 |
| 2025-03-07 | -0.20 |